News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Merck KGaA Falls; EU Rejects Erbitux for Lung Cancer
July 27, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Merck KGaA slumped the most in 14 years in Frankfurt trading after the European Union rejected its Erbitux drug for a form of lung cancer, denting growth prospects for the company’s top-selling oncology treatment.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Approvals
Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval
May 16, 2025
·
2 min read
·
Tristan Manalac
Government
RFK Jr. Firm on HHS Cuts, Wobbles on Measles Vaccine
May 15, 2025
·
2 min read
·
Tristan Manalac
Lung Cancer
AbbVie’s ADC Nabs Accelerated Approval for Lung Cancer
May 15, 2025
·
2 min read
·
Tristan Manalac
Podcast
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
May 14, 2025
·
2 min read
·
Heather McKenzie
